Skip to main content
. 2021 Oct 17;12(6):1456–1465. doi: 10.1002/jcsm.12828

Table 2.

Effects on primary and secondary endpoints (intention‐to‐treat analysis)

Variable Parameter estimate (95% confidence interval)
AT vs. AC P a RT vs. AC P a CT vs. AC P a Overall P a
Primary endpoint
VO2peak (mL O2·kg−1·min−1) 1.1 (0, 2.2) 0.04 −0.1 (−1.2, 1) 0.88 1.4 (0.2, 2.5) 0.02 0.02
Secondary endpoints
Resting cardiopulmonary function
Heart rate (b.p.m.) 2.1 (−2.8, 7.1) 0.39 2.7 (−2.4, 7.7) 0.30 −0.8 (−5.9, 4.3) 0.75 0.48
Systolic blood pressure (mmHg) 1.7 (−5.1, 8.6) 0.62 2.6 (−4.3, 9.4) 0.46 −1.6 (−8.7, 5.5) 0.65 0.64
Diastolic blood pressure (mmHg) 0.4 (−4.3, 5.2) 0.86 0.1 (−4.6, 4.8) 0.96 −0.6 (−5.5, 4.3) 0.80 0.98
Peak cardiopulmonary function
VO2peak (L.min−1) 0.1 (0, 0.1) 0.09 0 (−0.1, 0.1) 0.82 0.1 (0, 0.2) 0.005 0.02
Respiratory exchange ratio 0 (0, 0.1) 0.19 0 (−0.1, 0) 0.46 0 (−0.1, 0) 0.30 0.10
Ventilation (L.min−1) 4.0 (0.1, 7.9) 0.04 −0.7 (−4.6, 3.2) 0.73 4.2 (0.1, 8.2) 0.04 0.02
Heart rate (b.p.m.) 7.2 (1.7, 12.8) 0.01 1.4 (−4.2, 6.9) 0.63 3.3 (−2.5, 9) 0.26 0.06
Systolic blood pressure (mmHg) 4.2 (−5.7, 14.2) 0.40 3.8 (−6.3, 13.9) 0.46 4.3 (−6.5, 15) 0.43 0.82
Diastolic blood pressure (mmHg) 1.7 (−3.6, 7) 0.53 2.2 (−3, 7.5) 0.40 3.0 (−2.7, 8.7) 0.29 0.75
Strength
1‐RM leg press (lb) 5.3 (−15.1, 25.7) 0.61 24.2 (4.1, 44.4) 0.02 16.5 (−4.4, 37.3) 0.12 0.08
1‐RM chest press (lb) −0.6 (−13.4, 12.3) 0.93 20.4 (8.2, 32.6) <0.001 6.0 (−6.6, 18.7) 0.34 0.003
1‐RM seated row (lb) −7.6 (−15.6, 0.5) 0.06 7.7 (0.1, 15.3) 0.04 3.7 (−4.2, 11.5) 0.36 0.001
Body weight and composition
Weight (kg) 1.1 (0, 2.3) 0.06 0.6 (−0.6, 1.7) 0.33 0.2 (−0.9, 1.4) 0.71 0.25
Lean body mass (%) −1.0 (−2.8, 0.9) 0.29 1.6 (−0.2, 3.4) 0.08 1.1 (−0.8, 3) 0.25 0.03
Fat mass (%) 1.0 (−0.9, 2.8) 0.30 −1.6 (−3.4, 0.2) 0.08 −1.1 (−3, 0.8) 0.24 0.03
PROs
FACT‐L (0–136) 2.5 (−2.9, 7.9) 0.36 −2.0 (−7.1, 3.2) 0.46 −0.4 (−5.9, 5.2) 0.90 0.42
FACT‐G total (0–108) 1.7 (−4.3, 7.8) 0.57 −0.8 (−6.6, 5.1) 0.80 −1.1 (−7.4, 5.1) 0.72 0.79
Physical well‐being (0–28) 0 (−1.4, 1.4) 0.98 0.1 (−1.3, 1.5) 0.92 −1.2 (−2.6, 0.3) 0.11 0.27
Social well‐being (0–28) 1.4 (−0.9, 3.7) 0.22 −0.7 (−3, 1.5) 0.52 0.8 (−1.6, 3.2) 0.50 0.27
Emotional well‐being (0–24) −0.7 (−2.7, 1.3) 0.50 −0.8 (−2.7, 1.2) 0.45 −0.3 (−2.4, 1.7) 0.75 0.87
Functional well‐being (0–28) 2.0 (−0.4, 4.5) 0.10 −1.1 (−3.4, 1.3) 0.37 1.0 (−1.4, 3.5) 0.41 0.06
FACIT‐Fatigue (0–52) −1.7 (−3.8, 0.4) 0.11 0.1 (−2, 2.2) 0.93 −0.5 (−2.7, 1.7) 0.64 0.32
Pain (0–10) −0.3 (−0.8, 0.3) 0.37 0.2 (−0.4, 0.7) 0.52 −0.3 (−0.8, 0.3) 0.39 0.34
Sleep (0–28) −1.1 (−2.6, 0.4) 0.16 0.3 (−1.2, 1.9) 0.66 −0.8 (−2.4, 0.8) 0.33 0.22

AC, attention control; ANCOVA, analysis of covariance; AT, aerobic training; CT, combination training; FACIT, Functional Assessment of Chronic Illness Therapy; FACT‐G, Functional Assessment of Cancer Therapy—General; FACT‐L, Functional Assessment of Cancer Therapy—Lung; PROs, patient‐reported outcomes; RM, repetition maximum; RT, resistance training.

Data presented as parameter estimate (95% confidence interval) as estimated from ANCOVA model with outcome of change adjusted for baseline value and age, body mass index, and co‐morbidities (coronary artery disease, chronic obstructive pulmonary disease, and hypertension).

a

P‐value from ANCOVA model with outcome of change adjusted for baseline factors.